Discounted Cash Flow Rating

Buy

Return on Equity Rating

Sell

Debt to Equity Rating

Sell

Price to Earnings Rating

Strong Buy

Analyst Rating

Neutral

Simple Moving Average

Neutral

Exponential Moving Average

Neutral

Relative Strength Index

Strong Buy

Standard Deviation

Strong Sell

Williams %R

Strong Buy

Average Directional Index

Sell

Insider Trading

Strong Buy

Wall Street Data Solutions Rating

Neutral

B

Medicinova, Inc. (MNOV)

Pharmaceutical Preparations

https://www.medicinova.com

MediciNova Inc is a biopharmaceutical company. The company acquires and develops small-molecule therapeutics for the treatment of diseases with unmet medical needs with a specific focus on the U.S. market. Its products portfolio includes therapeutics such as MN-001, MN-166, MN-221 etc. The firm's current strategy is to focus its development activities on therapeutics for neurological disorders and fibrotic diseases.

4275 EXECUTIVE SQUARE, SUITE 300
LA JOLLA, CA

Current Price

---.--

% Change Today

0.00%

Change Amt. Today

0.00

Active Status

Active

Listing Date

12/07/2006

Market Cap

55,912,668

Shares Outstanding

49,050,000

Weighted SO

49,046,246

Total Employees

N/A

Upcoming Earnings

08/14/2024

Similar Tickers

AVTE --.--%

ADAG --.--%

ACRV --.--%

RZLT --.--%

ANTX --.--%

ELYM --.--%

MOLN --.--%

CSBR --.--%

Beta

0.7240

Last Div

0.0000

Range

1.12-2.49

Chg

-0.0200

Avg Vol

20701

Mkt Cap

55912668

Exch

NASDAQ

Country

US

Phone

858 373 1500

DCF Diff

0.0989

DCF

1.0561

Div Yield

0.0000

P/S

246.4286

EV Multiple

-0.0104

P/FV

0.9740

Div Yield %

0.0000

P/E

-6.8479

PEG

-0.1655

Payout

0.0000

Current Ratio

18.2433

Quick Ratio

18.2433

Cash Ratio

17.7751

DSO

0.0000

DIO

0.0000

Op Cycle

0.0000

DPO

11120.6331

CCC

-11120.6331

Gross Margin

0.9034

Op Margin

-5092.9984

Pretax Margin

-35.9725

Net Margin

-35.9859

Eff Tax Rate

140.4895

ROA

-0.1352

ROE

-0.1337

ROCE

-19.9546

NI/EBT

1.0004

EBT/EBIT

0.0071

EBIT/Rev

-5092.9984

Debt Ratio

0.0031

D/E

0.0033

LT Debt/Cap

0.0000

Total Debt/Cap

0.0033

Int Coverage

-25264.2295

CF/Debt

-44.9878

Equity Multi

1.0522

Rec Turnover

0.0000

Pay Turnover

0.0328

Inv Turnover

0.0000

FA Turnover

0.4737

Asset Turnover

0.0038

OCF/Share

-0.1743

FCF/Share

-0.1744

Cash/Share

0.9040

OCF/Sales

-37.6822

FCF/OCF

1.0004

CF Coverage

-44.9878

ST Coverage

-44.9878

CapEx Coverage

-2366.3955

Div&CapEx Cov

-2366.3955

P/BV

0.9740

P/B

0.9740

P/S

246.4286

P/E

-6.8479

P/FCF

-6.5369

P/OCF

-6.5397

P/CF

-6.5397

PEG

-0.1655

P/S

246.4286

EV Multiple

-0.0104

P/FV

0.9740

DPS

0.0000

Latest Headlines (EST)

GlobeNewswire Inc. Apr 14, 23:00 MediciNova To Participate in D. Boral’s Capital Global Conference on May 14, 2025 GlobeNewswire Inc. Nov 11, 23:00 MediciNova Given Notice of Monetary Damages Due Under Patent Settlement of Sanofi-Novartis GlobeNewswire Inc. Sep 03, 23:00 MediciNova Announces Acceptance of Abstract Regarding MN-166 (ibudilast) in COMBAT-ALS Clinical Trial for Presentation at the 2024 Annual NEALS (Northeast Amyotrophic Lateral Sclerosis Consortium) Meeting GlobeNewswire Inc. Jan 17, 06:00 MediciNova Receives a Notice of Grant for a New Patent Covering MN-166 (ibudilast) for the Treatment of Macular Injury in China GlobeNewswire Inc. Dec 21, 18:00 MediciNova Announces Abstract Regarding MN-166 (ibudilast) in Chlorine Gas-induced Lung Injury Accepted for Presentation at the 63rd Annual Meeting of the Society of Toxicology GlobeNewswire Inc. Dec 21, 18:00 MediciNova Announces Abstract Regarding MN-166 (ibudilast) in Chlorine Gas-induced Lung Injury Accepted for Presentation at the 63rd Annual Meeting of the Society of Toxicology GlobeNewswire Inc. Dec 21, 18:00 MediciNova Announces Abstract Regarding MN-166 (ibudilast) in Chlorine Gas-induced Lung Injury Accepted for Presentation at the 63rd Annual Meeting of the Society of Toxicology GlobeNewswire Inc. Dec 21, 18:00 MediciNova Announces Abstract Regarding MN-166 (ibudilast) in Chlorine Gas-induced Lung Injury Accepted for Presentation at the 63rd Annual Meeting of the Society of Toxicology GlobeNewswire Inc. Dec 21, 18:00 MediciNova Announces Abstract Regarding MN-166 (ibudilast) in Chlorine Gas-induced Lung Injury Accepted for Presentation at the 63rd Annual Meeting of the Society of Toxicology GlobeNewswire Inc. Dec 21, 18:00 MediciNova Announces Abstract Regarding MN-166 (ibudilast) in Chlorine Gas-induced Lung Injury Accepted for Presentation at the 63rd Annual Meeting of the Society of Toxicology GlobeNewswire Inc. Dec 21, 18:00 MediciNova Announces Abstract Regarding MN-166 (ibudilast) in Chlorine Gas-induced Lung Injury Accepted for Presentation at the 63rd Annual Meeting of the Society of Toxicology GlobeNewswire Inc. Dec 06, 18:00 MediciNova Receives a Notice of Decision to Grant for a New Patent Covering MN-166 (ibudilast) for the Treatment of Progressive MS in Europe GlobeNewswire Inc. Nov 19, 18:00 MediciNova Announces New Data and Results of a Phase 2 Clinical Trial of MN-166 (ibudilast) in Glioblastoma Presented at the 28th Annual Meeting of the Society for Neuro-Oncology GlobeNewswire Inc. Nov 19, 18:00 MediciNova Announces New Data and Results of a Phase 2 Clinical Trial of MN-166 (ibudilast) in Glioblastoma Presented at the 28th Annual Meeting of the Society for Neuro-Oncology GlobeNewswire Inc. Nov 19, 18:00 MediciNova Announces New Data and Results of a Phase 2 Clinical Trial of MN-166 (ibudilast) in Glioblastoma Presented at the 28th Annual Meeting of the Society for Neuro-Oncology GlobeNewswire Inc. Nov 19, 18:00 MediciNova Announces New Data and Results of a Phase 2 Clinical Trial of MN-166 (ibudilast) in Glioblastoma Presented at the 28th Annual Meeting of the Society for Neuro-Oncology GlobeNewswire Inc. Nov 19, 18:00 MediciNova Announces New Data and Results of a Phase 2 Clinical Trial of MN-166 (ibudilast) in Glioblastoma Presented at the 28th Annual Meeting of the Society for Neuro-Oncology GlobeNewswire Inc. Nov 19, 18:00 MediciNova Announces New Data and Results of a Phase 2 Clinical Trial of MN-166 (ibudilast) in Glioblastoma Presented at the 28th Annual Meeting of the Society for Neuro-Oncology GlobeNewswire Inc. Nov 19, 18:00 MediciNova Announces New Data and Results of a Phase 2 Clinical Trial of MN-166 (ibudilast) in Glioblastoma Presented at the 28th Annual Meeting of the Society for Neuro-Oncology GlobeNewswire Inc. Nov 19, 18:00 MediciNova Announces New Data and Results of a Phase 2 Clinical Trial of MN-166 (ibudilast) in Glioblastoma Presented at the 28th Annual Meeting of the Society for Neuro-Oncology

Revenue Product Segmentation